Hello All,
I thought I would delurk (on this thread) briefly and share something I received recently. I don't know if any or how many of you get the report from Union Securities (out of London, England - they are following Nortran and seem to feel pretty strongly about it.
Here is what they wrote:
"Last week, Nortran announced a licensing deal with Swiss pharmaceutical giant, F. Hoffman-La Roche (Roche), to test and develop a group of Nortran's entierrhythmic compounds for the prevention and treatment of atrial arrhythmies. Roche and Nortran will begin conducting a series of studies to further evaluate the safety and efficacy of Nortran's proprietary compounds in preclinical models of atris arrhymthmies. Under the terms of this agreement, Roche has paidd Nortran a fee for the exclusive option to a worldwide (except for the ASEAN nations) licence to these compounds. If Roche exercises its option, Notran will receive a licence fee as well as milestone payments upon reaching certain percentage of development and certain sales levels of a new drug. The maximum amount of such payments will be $86.5 million (US). In addition, Roche will pay a royalty on sales of any other product coming from the program. The shares have fallen sharply following the announcement, probably dueto local traders taking profits and the lack of any further mystery and the associated hype now that a deal has been done. The C$10,500,000 private placement is supposedly oversubscribed and should allow the Company to list on the TSE. The President, Robert Rieder is in Europ on a road show to explain the new deal to European investors."
Another stock I started following was in there as well - don't know how may of you follow IGT. Thought you might be interested
"IGT Pharma is a Vancouver-based emerging pharmaceutical company focused on the developing innovative and cost-effective synthetic processes for new and generic anti-cancer drugs. IGT received VSE approval of its acquisition of the remaining 65% of Precision Biochemicals Inc (PBI). Consideration paid to the the principals of PBI, Drs. Ken Currey and Martin Peet, was 478,905 shares og IGT. No other recent news other than the re-release of previous pre-clinical study data of favorable result for 'Anhydrovinblastine' when compared to Glaxo Wellcome's anti-cancer drug, Navelbine."
Back to Lurking.
Stan |
